Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658163 | 0.86 | PIK3CD (0.48) | PIK3CDKDM4ELMNARAB9A | |
| SCHEMBL15829026 | 0.85 | PIK3CD (0.37) | PIK3CD | |
| SCHEMBL15396011 | 0.83 | PIK3CD (0.43) | PIK3CD | |
| SCHEMBL15829027 | 0.82 | PIK3CD (0.41) | PIK3CD | |
| SCHEMBL20348164 | 0.82 | PIK3CD (0.33) | PIK3CDKDM4ELMNARAB9A | |
| SCHEMBL15033796 | 0.80 | PIK3CD (0.41) | PIK3CD | |
| SCHEMBL15829013 | 0.78 | PIK3CD (0.39) | PIK3CD | |
| SCHEMBL15033969 | 0.76 | PIK3CD (0.37) | PIK3CD | |
| SCHEMBL15033811 | 0.75 | PIK3CD (0.36) | PIK3CD | |
| SCHEMBL15033769 | 0.75 | PIK3CD (0.50) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807990-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-10800789-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200071337-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2020-03-05 | — | — | US | disclosed |
| US-20190276468-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2019-09-12 | — | — | US | disclosed |
| US-10344019-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2019-07-09 | — | — | US | disclosed |
| US-20180186806-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2018-07-05 | — | — | US | disclosed |
| US-9868745-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170369502-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-28 | — | — | US | disclosed |
| US-20170342085-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170342085-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-8921341-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140316144-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2014-10-23 | — | — | US | disclosed |
| US-20140178336-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2014-06-26 | — | — | US | disclosed |
| US-20140112885-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | Gelead Sciences, Inc. | 2014-01-16 | — | — | US | disclosed |
| US-20130309196-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2013-11-21 | — | — | US | disclosed |
| US-8575135-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130177530-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | PIK3CD 1022/4885KDM4E 2496/4885LMNA 1353/4885 |
| US-20130177530-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885KDM4E 3215/4885LMNA 1463/4885 |
| US-20170342085-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885KDM4E 3215/4885LMNA 1463/4885 |
| US-20200071337-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885KDM4E 3215/4885LMNA 1463/4885 |
| US-20130309196-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885KDM4E 3215/4885LMNA 1463/4885 |
| US-20180186806-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885KDM4E 3215/4885LMNA 1463/4885 |
| US-20140112885-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885KDM4E 3215/4885LMNA 1463/4885 |
| US-20170369502-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885KDM4E 3215/4885LMNA 1463/4885 |
| US-10344019-B2 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | PIK3CD 1022/4885KDM4E 2496/4885LMNA 1353/4885 |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885KDM4E 3215/4885LMNA 1463/4885 |
| US-20190276468-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885KDM4E 3215/4885LMNA 1463/4885 |
| US-10807990-B2 | Antiviral compounds | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885KDM4E 3215/4885LMNA 1463/4885 |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885KDM4E 3215/4885LMNA 1463/4885 |
| US-20140178336-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885KDM4E 3215/4885LMNA 1463/4885 |
| US-10800789-B2 | Antiviral compounds | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885KDM4E 3215/4885LMNA 1463/4885 |
| US-20140316144-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885KDM4E 3215/4885LMNA 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.